Compounded Dual-Incretin Formulation / B12
Compounded dual GIP / GLP-1 agonist with Cyanocobalamin
- Format
- Injectable
- Spec
- Multiple concentrations
- Sourcing
- FDA-registered 503A pharmacy
Research Summary
Mechanism & Physiological Role
Dual agonist acting on both GIP and GLP-1 receptors, enhancing glucose-dependent insulin release, improving lipid handling, and inducing greater weight reduction than GLP-1 monotherapy in clinical trials.
Clinical & Research Applications
Discussed in the peer-reviewed literature in the context of weight management and dual-incretin metabolic research. 503A compounded formulations are prepared per individual patient prescriptions.
Scientific Publications
Peer-Reviewed References
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
New England Journal of Medicine · 2022 · PMID: 35658024
All compounded formulations are prepared by a licensed 503A sterile compounding pharmacy partner. Compounds are available to NPI-verified licensed practitioners only, per individual patient prescriptions in accordance with applicable state and federal law. Compounded medications are not FDA-approved. Pricing available upon verified account approval.
Ready to add Compounded Dual-Incretin Formulation / B12 to your protocol?
Compounded formulations are dispensed by our licensed 503A pharmacy partner OBPRx under a valid patient-specific prescription. Prefer a formal quote? Request formulation-specific pricing instead.